REPLIGEN CORP (RGEN)
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Medical - Instruments & Supplies
Repligen Corporation
Trials need funding. See this company's dilution risk and cash position.
- Phase 3Terminated
Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction
RG1068 (Synthetic Human Secretin)
Autism
NCT00036231Enrollment-StartApr 2002Primary Completion-Completion- - Phase 3Completed
Synthetic Human Secretin in Children With Autism
RG1068 (Synthetic Human Secretin)
Autism
NCT00036244Enrollment-StartApr 2002Primary Completion-CompletionJan 2004 - Phase 3Completed
Safety and Efficacy of Synthetic Human Secretin-Enhanced MRCP in Subjects With Abnormalities of the Pancreas
RG1068 (synthetic human secretin)
Pancreatitis
NCT00660335Enrollment258StartMar 2008Primary CompletionOct 2009CompletionOct 2009 - Phase 2Completed
Phase II Study to Assess RG2417 in the Treatment of Bipolar I Depression
Uridine
Bipolar Depression
NCT00322764Enrollment80StartMar 2006Primary Completion-Completion- - Phase 2Completed
A Study to Assess the Safety, Tolerability and Efficacy of RG2417 in Bipolar I Depression
RG2417, Placebo
Bipolar I Depression
NCT00812058Enrollment180StartNov 2008Primary CompletionDec 2010CompletionDec 2010 - Phase 1Terminated
RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease
RG2133 (2',3',5'-tri-O-acetyluridine)
Mitochondrial Diseases
NCT00060515Enrollment12Start-Primary Completion-Completion-
| Drug / Therapy | Link | ||
|---|---|---|---|
| Phase 3 | Terminated | RG1068 (Synthetic Human Secretin) | NCT00036231 |
| Phase 3 | Completed | RG1068 (Synthetic Human Secretin) | NCT00036244 |
| Phase 3 | Completed | RG1068 (synthetic human secretin) | NCT00660335 |
| Phase 2 | Completed | Uridine | NCT00322764 |
| Phase 2 | Completed | RG2417, Placebo | NCT00812058 |
| Phase 1 | Terminated | RG2133 (2',3',5'-tri-O-acetyluridine) | NCT00060515 |